Onconex Esophageal Cancer (Somatic) near me in Ernakulam

Esophageal cancer is the 8th most common cancer worldwide, and the 6th most common cause of cancer related deaths. A majority of esophageal malignancies are either esophageal squamous cell carcinoma (ESCC) or esophageal adenocarcinoma (EAC). Both esophageal squamous cell carcinoma and esophageal adenocarcinoma are aggressive cancers with poor patient response to conventional chemotherapy and radiation treatment.

EGFR amplification and/or overexpression has been detected in a wide variety of ESCC samples, ranging from 7% to greater than 60%, and has been associated with adverse prognosis. Comprehensive genomic profiling shows significant promise in identifying clinically relevant genomic alterations in both ESCC and EAC and informs the potential use of targeted therapies in both major types of esophageal cancer.

Clinical Utility:

• To identify driver mutations - mutation in the DNA Sequence that cause cells to become cancers, grow & spread in body.
• In drug profiling for Chemotherapy & Targeted Drugs.
• In predictive genomic biomarker identification to guide the therapeutic process.
• The targeted NGS panel offers wide coverage and in-depth analysis to detect the known and novel variants.
• The multigene approach reduces the time for diagnosis providing a more economical solution.

Panels covered:

• Comprehensive genomic profiling for 100 cancer genes associated with esophageal cancer.
• Screening for clinically significant genes based on National Comprehensive Cancer Network (NCCN) guidelines.
• Genetic counselling to guide through the report and discuss the available management & treatment options in case of clinical findings.
• Reporting - Pathogenic and Likely Pathogenic Variants are reported following the ACMG recommended guidelines.
• Best in class Bioinformatics pipeline for the most accurate analysis by our experienced Bioinformatics team.

Who Should Get Tested?

• Patients diagnosed with esophageal cancer (ESCC or EAC) seeking personalized treatment options.
• Individuals with a family history of esophageal cancer.
• Patients with poor response to conventional chemotherapy and radiation treatments.
• Clinicians looking for comprehensive genomic profiling to inform targeted therapies.

What Does the Report Tell Me?

The Onconex Esophageal Cancer (Somatic) test report provides detailed insights into the genetic mutations driving esophageal cancer. It identifies driver mutations, informs drug profiling for chemotherapy and targeted drugs, and highlights predictive genomic biomarkers to guide the therapeutic process. The report includes pathogenic and likely pathogenic variants following ACMG guidelines, offering a clear understanding of the molecular underpinnings of the tumor and potential treatment options.

Next Steps Post Getting the Report:

After receiving the Onconex Esophageal Cancer (Somatic) test report, the following steps are recommended:

• Schedule a genetic counseling session to interpret the results and discuss available management and treatment options.
• Discuss the report with your healthcare provider to tailor the treatment plan based on the genetic profile of the tumor.
• Consider targeted therapies and other personalized treatment options informed by the genomic insights provided in the report.
• Utilize the free genetic counseling offered to navigate the results, explore therapeutic strategies, and make informed decisions about your treatment plan.

Note: Pre-test & post-test genetic counseling can be provided. If interested please send the request to this email id: [email protected]  

Disclaimer: In no event shall the liability of TATA 1MG exceed the amount of actual cost of test charges incurred by the customer as stated on the invoice issued by Tata 1mg.